Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre,open-label,randomised, phase 3 trial |
| |
| Affiliation: | 1. Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn Duesseldorf, German CLL Study Group, University Hospital, University of Cologne, Germany;2. Roche Products Limited, Welwyn Garden City, UK;3. Regional Clinical Hospital NA Semashko, Nizhny Novgorod, Russia;4. Division of Onco-Hematology, Santa Maria Terni Hospital, University of Perugia, Perugia, Italy;5. Department of Malignant Hematology, H Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA;6. Haematology Department, School of Clinical Sciences at Monash Health, Monash University, VIC, Australia;7. First Internal Department, MHAT Hristo Botev, AD, Vratsa, Bulgaria;8. Hematology Department, Clinique Le Mans, France;9. Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil;10. Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark;11. Wellington Blood and Cancer Centre, Capital and Coast District Health Board and Malaghan Institute of Medical Research, Wellington, New Zealand;12. Queen Elizabeth II Health Science Center, Halifax, NS, Canada;13. Moores Cancer Center, University of California San Diego, San Diego, CA, USA;14. Department III of Internal Medicine, Ulm University, Ulm, Germany;15. AbbVie, North Chicago, IL, USA;p. Department II of Internal Medicine, Campus Kiel, University of Schleswig-Holstein, Kiel, Germany;q. Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany |
| |
| Abstract: | |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
